HHorinouchi· @HHorinouchi · X·· 2 天前评分60
正文 · 原文
🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥Overall Survival (OS) Analysis of Telisotuzumab Adizutecan in Patients (Pts) With Nonsquamous Non-Small Cell Lung Cancer (NSQ NSCLC): Phase 1 First-in-Human Study 🎙️Dr. David Sommerhalder 🔢2658RO 🎯Median OS 13.8mo (EGFR WT, n=48) and 16.2mo (EGFR MUT, n=41) in Heavily Pretreated Pts 🎯Longer OS in High c-Met Expressers (25.2mo, EGFR WT ≥3+/≥10%) ☑️NCT05029882 🔗 https://t.co/E2MIRGnkpb @OncoAlert @Larvol @myESMO @IASLC
热度 0 · 0 赞 · 0 回复 · 0 转发
会议摘要
NCT05029882NCT05029882按 - **标题 / Title：** Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab 对上
- **标题 / Title：** Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab读摘要原文 →来源：HHorinouchi · x.com